CureVac NV (CVAC)
3.47
+0.21
(+6.44%)
USD |
NASDAQ |
Jun 24, 16:00
3.465
0.00 (0.00%)
After-Hours: 20:00
CureVac Research and Development Expense (Annual): 125.28M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 125.28M |
| December 31, 2022 | 65.96M |
| December 31, 2021 | 965.36M |
| Date | Value |
|---|---|
| December 31, 2020 | 129.97M |
| December 31, 2019 | 48.41M |
| December 31, 2018 | 49.27M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
48.41M
Minimum
2019
965.36M
Maximum
2021
267.00M
Average
125.28M
Median
2023
Research and Development Expense (Annual) Benchmarks
| BioNTech SE | 1.930B |
| Affimed NV | 102.80M |
| Moderna Inc | 4.845B |
| InflaRx NV | 44.41M |
| MorphoSys AG | 307.04M |